The inflammatory breast cancer survival rate is sometimes used as a standard way for physicians and researchers to predict a patient’s prognosis. While some patients find this information helpful, others do not, so learning about survival rates is largely a matter of personal preference.
Survival rates are often referred to in terms of median survival, which is the length of time for half of the patients in a large group to survive. It is important to keep in mind that the median is simply a point of reference that is used by physicians and researchers. No single patient can be considered average, and it is impossible to predict what will happen in any individual case. Many patients experience much better outcomes than the median suggests. Additionally, there are many factors that the median does not take into account, including risk factors that can influence a patient’s outcome.
Nevertheless, there are several factors that have been found to improve the survival rate of inflammatory breast cancer patients, such as:
- Early detection
- Aggressive treatment, including chemotherapy and radiation
- How well the cancer responds to treatment
- Eligibility for surgery
- Overall health and wellness
As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt Cancer Center is proud to be positioned at the forefront of cancer research. We are able to offer our patients a wide range of clinical trials and the very latest in treatment options, along with comprehensive care and compassionate support to enhance each patient’s quality of life.
If you have any questions about the inflammatory breast cancer survival rate, Moffitt is here to help. Call Moffitt at 1-888-663-3488, or fill out our new patient registration form online to get started. No referral is necessary to meet with our breast cancer team.
